Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Mecamylamine for Autonomic Dysreflexia Prophylaxis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03914677
Recruitment Status : Recruiting
First Posted : April 15, 2019
Last Update Posted : October 7, 2019
Sponsor:
Information provided by (Responsible Party):
Edward Nieshoff, MD, Wayne State University

Brief Summary:
This is a preliminary study of the antihypertensive drug mecamylamine, used in the specific circumstance of hypertension caused by autonomic dysreflexia (AD), a condition that affects people with spinal cord injury (SCI). Initially, mild sensory stimulation of subjects' legs is used to intentionally provoke AD, as reflected by blood pressure elevation during such stimulation. In subsequent testing sessions, mecamylamine is given prior to sensory stimulation, to show the effect of the drug on preventing these AD-related blood pressure elevations.

Condition or disease Intervention/treatment Phase
Spinal Cord Injuries Drug: Mecamylamine Oral Tablet Phase 4

  Hide Detailed Description

Detailed Description:

In this one year pilot study we will enroll 3-5 people with SCI, and aim to develop a simple, convenient BP cuff method to elicit AD (i.e., using a BP cuff applied to the leg as a mild noxious stimulus), and then use that method to preliminarily evaluate the effects of the antihypertensive drug mecamylamine on AD. Study participants will complete up to 5 research visits, will undergo AD provocation using the leg cuff protocol, and will receive escalating doses of mecamylamine, as needed and tolerated, in order to prevent AD:

After signing the informed consent form, at visit 1, subjects will complete an interview to evaluate past medical history, an autonomic dysfunction questionnaire, a physical examination (including an autonomic assessment and specialty SCI exam), vital signs measurement, and baseline testing of the electrical activity of the heart (electrocardiography or ECG testing).

At visit 2, subjects will complete a preparation procedure including: baseline vital signs measurement, an interview to document all medications and/or supplements taken in the prior 24 hours, confirmation of completed bladder/bowel evacuation before the visit, confirmation of no significant illness/injury since last visit, and documentation of any meals before the visit. Next, the subject will be connected to an ECG monitor and a (second) BP cuff will be applied to the arm (for measuring BP response to the leg cuff procedure). With the ECG and arm cuff in place, s/he will undergo the AD provocation procedure: The BP cuff placed around the leg just below the knee will be inflated for up to 10 minutes, as a means of providing sensory stimulation to elicit AD. BP will be measured using the arm cuff every 2 minutes during the leg cuff inflation, and periodically after the leg cuff is deflated, until BP and heart rate are back to baseline values. Physical manifestations and symptoms of AD will be recorded during the period of leg cuff inflation and thereafter, throughout recovery. This BP cuff protocol will be repeated twice during the same visit, with trials separated by a 30-minute recovery period. The leg cuff will be deflated immediately if the blood pressure-measuring cuff shows that systolic BP exceeds 180 mmHg, diastolic BP exceeds 100 mmHg, heart rate is less than 40 or greater than 100 beats per minute, adverse ECG changes are evident, or symptoms are unacceptable to the subject. An established safety plan will be followed in the event of a significant adverse reaction to the leg compression or study drug. If the leg cuff inflation fails to elicit AD, then the subject will be dropped from the study.

At visit 3, a similar visit preparation procedure will be completed as in visit 2. Three hours prior to AD provocation testing with the leg cuff, subjects will receive 2.5 mg of mecamylamine in tablet form, to try to prevent AD. Physical manifestations and symptoms of AD will be recorded during the period of cuff inflation and thereafter, throughout recovery. The leg cuff will be deflated after 10 minutes, or immediately as appropriate according to the same criteria as listed for visit 2. After a 30-minute recovery, the leg cuff inflation will be repeated once during the same session, to confirm whether or not 2.5 mg of mecamylamine eliminates AD, or at least reduces the associated BP elevation, as well as the other manifestations and symptoms. If the dose of 2.5 mg mecamylamine is effective, the subject will not be asked to return for testing with a higher dose and study participation will end with visit 3. If either trial of leg cuff inflation still elicits AD despite premedication with 2.5 mg mecamylamine, then s/he will be scheduled to come back for visit 4.

At visit 4, the visit preparation will be completed as in visits 2 and 3. Three hours prior to testing with the AD provocation procedure, 5 mg of mecamylamine will be given to the participant to try to prevent AD, since the lower dose failed to do so. The same procedures described above for visit 3 will be followed; subjects will again undergo 2 trials of AD provocation with the leg squeezing procedure. If both are successful (i.e., no AD is observed), the subject's participation in the study will end. If, despite premedication with mecamylamine 5 mg, the subject still experiences AD, then s/he will be asked to return for visit 5.

At visit 5, all the procedures as in visit 4 will be repeated, except that subjects will receive 7.5 mg of mecamylamine. Regardless if the medication does not prevent AD, subjects will not be scheduled to come for a follow up, as no further dose escalation will be attempted.

If at visit 3, 4, or 5 a subject experiences symptomatic low blood pressure after taking mecamylamine (manifest as dizziness, lightheadedness, or change in vision; this is considered unlikely based on the published literature), s/he will be asked to drink several glasses of cold water, and possibly to lay down for up to 30 minutes to try to alleviate those symptoms. In the event symptomatic low blood pressure persists, the subject will be given 10 mg of midodrine, a medication to elevate blood pressure. Midodrine would be expected to promptly (in less than an hour) elevate blood pressure and alleviate those symptoms. Upon adequate elevation of blood pressure to cause resolution of the symptoms, the subject will be discharged from the study, because of the adverse effect of mecamylamine. If the midodrine 10 mg fails to resolve symptomatic low blood pressure, then further evaluation and treatment will be provided as appropriate (e.g., intravenous fluids). The latter scenario is considered to be extremely unlikely.

note - visits will be separated by no more than one month


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 5 participants
Intervention Model: Sequential Assignment
Intervention Model Description: dose-escalation
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Pilot Study of Mecamylamine for Autonomic Dysreflexia Prophylaxis
Actual Study Start Date : June 13, 2019
Estimated Primary Completion Date : March 17, 2020
Estimated Study Completion Date : December 31, 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Mecamylamine Oral Tablet
Initial dose - mecamylamine 2.5 mg tablet po 3 hours prior to provocative testing; subsequent dose escalations as needed, to 5 mg and then 7.5 mg, using the same testing methodology.
Drug: Mecamylamine Oral Tablet
nicotinic antagonist (ganglionic blocker)
Other Name: Vecamyl




Primary Outcome Measures :
  1. change in systolic blood pressure [ Time Frame: 10 minutes (following initiation of sensory stimulation) ]
    difference in systolic blood pressure during leg cuff inflation vs during unstimulated baseline

  2. change in heart rate [ Time Frame: 10 minutes (following initiation of sensory stimulation) ]
    difference in heart rate during leg cuff inflation vs during unstimulated baseline


Secondary Outcome Measures :
  1. signs and symptoms of autonomic dysreflexia [ Time Frame: 10 minutes (following initiation of sensory stimulation) ]
    piloerection, diaphoresis, headache



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • chronic (>1 year) SCI at T6 or above, American Spinal Injury Association grade A, B, or C
  • negative serum pregnancy test for females

Exclusion Criteria:

  • history of arrhythmia, cardiovascular disease, cerebral aneurysm
  • contraindications to use of mecamylamine or midodrine (pregnancy, nursing, glaucoma, kidney disease, pyloric stenosis, arteriosclerosis, or concurrent use of a sulfonamide antibiotic)
  • dependence on reflex voiding for bladder management (mecamylamine may cause urinary retention)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03914677


Contacts
Layout table for location contacts
Contact: Daniela Ristova-Trendov, MD 313/745-0590 dristova@med.wayne.edu
Contact: EDWARD C NIESHOFF, MD 2485147659 ecnieshoff@gmail.com

Locations
Layout table for location information
United States, Michigan
Wayne State University Recruiting
Detroit, Michigan, United States, 48201
Contact: Daniela Ristova-Trendov, MD    313-745-0590    dristova@med.wayne.edu   
Contact: EDWARD C NIESHOFF, MD    2485147659    ecnieshoff@gmail.com   
Sponsors and Collaborators
Wayne State University
Investigators
Layout table for investigator information
Principal Investigator: EDWARD C NIESHOFF, MD Wayne State University

Publications:
Layout table for additonal information
Responsible Party: Edward Nieshoff, MD, Principal Investigator, Wayne State University
ClinicalTrials.gov Identifier: NCT03914677     History of Changes
Other Study ID Numbers: 080518MP2F
First Posted: April 15, 2019    Key Record Dates
Last Update Posted: October 7, 2019
Last Verified: October 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: De-identified participant data will be made available for all primary and secondary outcomes.
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Informed Consent Form (ICF)
Clinical Study Report (CSR)
Time Frame: Within 6 months following completion of the study through 5 years after completion.
Access Criteria: Data access requests will be reviewed by the Research Director of the sponsoring Wayne State University Department of Physical Medicine and Rehabilitation. Data will be made available to researchers who provide a methodologically sound proposal.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
Keywords provided by Edward Nieshoff, MD, Wayne State University:
Spinal Cord Injuries
autonomic dysreflexia
mecamylamine
Additional relevant MeSH terms:
Layout table for MeSH terms
Spinal Cord Injuries
Autonomic Dysreflexia
Spinal Cord Diseases
Central Nervous System Diseases
Nervous System Diseases
Trauma, Nervous System
Wounds and Injuries
Autonomic Nervous System Diseases
Mecamylamine
Antihypertensive Agents
Ganglionic Blockers
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Nicotinic Antagonists
Cholinergic Antagonists
Cholinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action